Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

HMGB1 Protein Interactions in Prostate and Ovary Cancer Models Reveal Links to RNA Processing and Ribosome Biogenesis through NuRD, THOC and Septin Complexes

  • Barreiro-Alonso, Aida
  • Lamas, Mónica
  • Lorenzo-Catoira, Lidia
  • Pardo, Mercedes
  • Yu, Lu
  • Choudhary, Jyoti
  • Cerdán, María Esperanza
[Abstract] This study reports the HMGB1 interactomes in prostate and ovary cancer cells lines. Affinity purification coupled to mass spectrometry confirmed that the HMGB1 nuclear interactome is involved in HMGB1 known functions such as maintenance of chromatin stability and regulation of transcription, and also in not as yet reported processes such as mRNA and rRNA processing. We have identified an interaction between HMGB1 and the NuRD complex and validated this by yeast-two-hybrid, confirming that the RBBP7 subunit directly interacts with HMGB1. In addition, we describe for the first time an interaction between two HMGB1 interacting complexes, the septin and THOC complexes, as well as an interaction of these two complexes with Rab11. Analysis of Pan-Cancer Atlas public data indicated that several genes encoding HMGB1-interacting proteins identified in this study are dysregulated in tumours from patients diagnosed with ovary and prostate carcinomas. In PC-3 cells, silencing of HMGB1 leads to downregulation of the expression of key regulators of ribosome biogenesis and RNA processing, namely BOP1, RSS1, UBF1, KRR1 and LYAR. Upregulation of these genes in prostate adenocarcinomas is correlated with worse prognosis, reinforcing their functional significance in cancer progression., This research was funded by the Wellcome Trust (grant no. 206194/Z/17/Z) and by Plan Estatal I+D+i, Instituto Carlos III (ISCIII, Spain) (grants no. PI14/01031 and PI18/01417) cofunded by the Fondo Europeo de Desarrollo Regional-FEDER (The European Regional Development Fund-ERDF) “A way of Making Europe”, and by Xunta de Galicia (Consolidación Grupos Referencia Competitiva grant no. ED431C 2020-08), Reino Unido. Wellcome Trust; 206194/Z/17/Z, Xunta de Galicia; ED431C 2020-08
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

The HMGB1-2 Ovarian Cancer Interactome: the Role of HMGB Proteins and Their Interacting Partners MIEN1 and NOP53 in Ovary Cancer and Drug-Response

  • Cámara-Quílez, M.
  • Barreiro-Alonso, Aida
  • Vizoso-Vázquez, Ángel
  • Rodríguez-Belmonte, Esther
  • Quindós-Varela, María
  • Lamas, Mónica
  • Cerdán, María Esperanza
[Abstract] High mobility group box B (HMGB) proteins are overexpressed in different types of cancers such as epithelial ovarian cancers (EOC). We have determined the first interactome of HMGB1 and HMGB2 in epithelial ovarian cancer (the EOC-HMGB interactome). Libraries from the SKOV-3 cell line and a primary transitional cell carcinoma (TCC) ovarian tumor were tested by the Yeast Two Hybrid (Y2H) approach. The interactome reveals proteins that are related to cancer hallmarks and their expression is altered in EOC. Moreover, some of these proteins have been associated to survival and prognosis of patients. The interaction of MIEN1 and NOP53 with HMGB2 has been validated by co-immunoprecipitation in SKOV-3 and PEO1 cell lines. SKOV-3 cells were treated with different anti-tumoral drugs to evaluate changes in HMGB1, HMGB2, MIEN1 and NOP53 gene expression. Results show that combined treatment of paclitaxel and carboplatin induces a stronger down-regulation of these genes in comparison to individual treatments. Individual treatment with paclitaxel or olaparib up-regulates NOP53, which is expressed at lower levels in EOC than in non-cancerous cells. On the other hand, bevacizumab diminishes the expression of HMGB2 and NOP53. This study also shows that silencing of these genes affects cell-viability after drug exposure. HMGB1 silencing causes loss of response to paclitaxel, whereas silencing of HMGB2 slightly increases sensitivity to olaparib. Silencing of either HMGB1 or HMGB2 increases sensitivity to carboplatin. Lastly, a moderate loss of response to bevacizumab is observed when NOP53 is silenced., This work has been funded by the Projects Nº PI14/01031 and PI18/01714, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 of the ISCIII- General Subdirection of Assesment and Promotion of the Research – European Regional Development Fund (FEDER) “A way of making Europe”. Funding is also acknowledged from Xunta de Galicia (Consolidación Grupos Referencia Competitiva Contract no. ED431C 2016–012). Aida Barreiro-Alonso was funded by a predoctoral fellowship from Xunta de Galicia-2013 (Spain) cofinanced by FEDER, Xunta de Galicia; ED431C 2016–012
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Thanksgiving to Yeast, the HMGB Proteins History from Yeast to Cancer [Review]

  • Lamas, Mónica
  • Vizoso-Vázquez, Ángel
  • Barreiro-Alonso, Aida
  • Cámara-Quílez, M.
  • Cerdán, María Esperanza
This article belongs to the Special Issue Yeasts Biochemistry and Biotechnology, [Abstract] Yeasts have been a part of human life since ancient times in the fermentation of many natural products used for food. In addition, in the 20th century, they became powerful tools to elucidate the functions of eukaryotic cells as soon as the techniques of molecular biology developed. Our molecular understandings of metabolism, cellular transport, DNA repair, gene expression and regulation, and the cell division cycle have all been obtained through biochemistry and genetic analysis using different yeasts. In this review, we summarize the role that yeasts have had in biological discoveries, the use of yeasts as biological tools, as well as past and on-going research projects on HMGB proteins along the way from yeast to cancer., This research was funded by Plan Estatal I+D+i, Instituto de Salud Carlos III (ISCIII, Spain) (grant nos. PI14/01031 and PI18/01417) and Ministerio de Ciencia e Innovación (grant no. PID2021-124564OB-I00), and cofunded by the Fondo Europeo de Desarrollo Regional-FEDER (The European Regional Development Fund-ERDF) “A way of Making Europe” and by Xunta de Galicia (Consolidación Grupos Referencia Competitiva grant no. ED431C 2020-08), Xunta de Galicia; ED431C 2020-08
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Identification of lncRNAs Deregulated in Epithelial Ovarian Cancer Based on a Gene Expression Profiling Meta-Analysis

  • Salamini-Montemurri, Martín
  • Lamas, Mónica
  • Lorenzo-Catoira, Lidia
  • Vizoso-Vázquez, Ángel
  • Barreiro-Alonso, Aida
  • Rodríguez-Belmonte, Esther
  • Quindós-Varela, María
  • Cerdán, María Esperanza
This article belongs to the Special Issue Non-coding RNAs' Functionality-Diagnosis and Therapy in Cancer and Other Indications, [Abstract] Epithelial ovarian cancer (EOC) is one of the deadliest gynecological cancers worldwide, mainly because of its initially asymptomatic nature and consequently late diagnosis. Long non-coding RNAs (lncRNA) are non-coding transcripts of more than 200 nucleotides, whose deregulation is involved in pathologies such as EOC, and are therefore envisaged as future biomarkers. We present a meta-analysis of available gene expression profiling (microarray and RNA sequencing) studies from EOC patients to identify lncRNA genes with diagnostic and prognostic value. In this meta-analysis, we include 46 independent cohorts, along with available expression profiling data from EOC cell lines. Differential expression analyses were conducted to identify those lncRNAs that are deregulated in (i) EOC versus healthy ovary tissue, (ii) unfavorable versus more favorable prognosis, (iii) metastatic versus primary tumors, (iv) chemoresistant versus chemosensitive EOC, and (v) correlation to specific histological subtypes of EOC. From the results of this meta-analysis, we established a panel of lncRNAs that are highly correlated with EOC. The panel includes several lncRNAs that are already known and even functionally characterized in EOC, but also lncRNAs that have not been previously correlated with this cancer, and which are discussed in relation to their putative role in EOC and their potential use as clinically relevant tools., This research was funded by the Plan Estatal I + D + i, Instituto de Salud Carlos III (ISCIII, Spain grant no. PI18/01417) and the Ministerio de Ciencia e Innovación (grant no. PID2021-124564OB-I00), and co-funded by the Fondo Europeo de Desarrollo Regional-FEDER (The European Regional Development Fund-ERDF) “A way of Making Europe” and by the Xunta de Galicia (Consolidación Grupos Referencia Competitiva grant no. ED431C 2020-08). M.S.-M. acknowledges the Ministry of Science, Innovation, and Universities of Spain for funding through an FPU fellowship, Xunta de Galicia; ED431C 2020-08
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

The Effect of HMGB1 and HMGB2 on Transcriptional Regulation Differs in Neuroendocrine and Adenocarcinoma Models of Prostate Cancer

  • Salamini-Montemurri, Martín
  • Vizoso-Vázquez, Ángel
  • Barreiro-Alonso, Aida
  • Lorenzo-Catoira, Lidia
  • Rodríguez-Belmonte, Esther
  • Cerdán, María Esperanza
  • Lamas, Mónica
This article belongs to the Special Issue Recent Molecular Biology on Ovarian Cancer and Prostate Cancer, [Abstract] Human high-mobility group-B (HMGB) proteins regulate gene expression in prostate cancer (PCa), a leading cause of oncological death in men. Their role in aggressive PCa cancers, which do not respond to hormonal treatment, was analyzed. The effects of HMGB1 and HMGB2 silencing upon the expression of genes previously related to PCa were studied in the PCa cell line PC-3 (selected as a small cell neuroendocrine carcinoma, SCNC, PCa model not responding to hormonal treatment). A total of 72% of genes analyzed, using pre-designed primer panels, were affected. HMGB1 behaved mostly as a repressor, but HMGB2 as an activator. Changes in SERPINE1, CDK1, ZWINT, and FN1 expression were validated using qRT-PCR after HMGB1 silencing or overexpression in PC-3 and LNCaP (selected as an adenocarcinoma model of PCa responding to hormonal treatment) cell lines. Similarly, the regulatory role of HMGB2 upon SERPINE1, ZWINT, FN1, IGFPB3, and TYMS expression was validated, finding differences between cell lines. The correlation between the expression of HMGB1, HMGB2, and their targets was analyzed in PCa patient samples and also in PCa subgroups, classified as neuroendocrine positive or negative, in public databases. These results allow a better understanding of the role of HMGB proteins in PCa and contribute to find specific biomarkers for aggressive PCa., This research was funded by the Plan Estatal I + D + i, Instituto de Salud Carlos III (ISCIII, Spain, grant no. PI18/01417 and Fortalece FORT23/00010) and the Ministerio de Ciencia e Innovación (grant no. PID2021-124564OB-I00), and co-funded by the Fondo Europeo de Desarrollo Regional-FEDER (The European Regional Development Fund-ERDF) “A way of Making Europe” and by the Xunta de Galicia (Consolidación Grupos Referencia Competitiva, grant no. ED431C 2020-08). M.S.-M. acknowledges the Ministry of Science, Innovation, and Universities of Spain for funding through an FPU fellowship, Xunta de Galicia; ED431C 2020-08
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

The Challenges and Opportunities of lncRNAs in Ovarian Cancer Research and Clinical Use

  • Salamini-Montemurri, Martín
  • Lamas, Mónica
  • Barreiro-Alonso, Aida
  • Vizoso-Vázquez, Ángel
  • Rodríguez-Belmonte, Esther
  • Quindós-Varela, María
  • Cerdán, María Esperanza
[Abstract] Ovarian cancer is one of the most lethal gynecological malignancies worldwide because it tends to be detected late, when the disease has already spread, and prognosis is poor. In this review we aim to highlight the importance of long non-coding RNAs (lncRNAs) in diagnosis, prognosis and treatment choice, to make progress towards increasingly personalized medicine in this malignancy. We review the effects of lncRNAs associated with ovarian cancer in the context of cancer hallmarks. We also discuss the molecular mechanisms by which lncRNAs become involved in cellular physiology; the onset, development and progression of ovarian cancer; and lncRNAs’ regulatory mechanisms at the transcriptional, post-transcriptional and post-translational stages of gene expression. Finally, we compile a series of online resources useful for the study of lncRNAs, especially in the context of ovarian cancer. Future work required in the field is also discussed along with some concluding remarks., This work was funded by Plan Estatal I + D + I by the Instituto de Salud Carlos III (ISCIII, Spain) under grant agreement AES number PI18/01714, cofounded by Fondo Europeo de Desarrollo Regional-FEDER (The European Regional Development Fund-ERDF) “A way of Making Europe,” and by Xunta de Galicia (Consolidación Grupos Referencia Competitiva contract number ED431C 2016-012). M.S.M. was funded by a predoctoral fellowship from FPU-2018 (Spain), Xunta de Galicia; ED431C 2016-012